Bibliographic Info
GuidelineWHO consolidated guidelines on tuberculosis: Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update
Year of Publication2022
Issuing InstitutionWorld Health Organization
Recommendation
Status
Maintained
Recommended in favor
Conditional
Certainty of evidence
Very low
The 9-month all-oral regimen for multidrug- or rifampicin-resistant tuberculosis (MDR/RR-TB): WHO suggests the use of the 9-month all-oral regimen rather than longer (18-month) regimens in patients with MDR/RR-TB and in whom resistance to fluoroquinolones has been excluded.
Also Featured In
This recommendation also appears in the following guidelines:
Guideline
WHO consolidated guidelines on tuberculosis: module 4: treatment and care
Year2025
InstitutionWorld Health Organization